GlassScriptPhysician profile
Bradley Hunter Barrett
NPI 1093781775
$2,166.54
in general payments reported to CMS, 2019-2025
34 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.21 · 2020: $36.05 · 2021: $203 · 2022: $410 · 2023: $285 · 2024: $602 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $230.11 | 2019-2025 | Grafix Pl, Renasys Go V2 Home, Collagenase Santyl |
| Amgen INC. | $211.58 | 2021-2025 | Evenity, Prolia, Prolia |
| Reapplix INC. | $207.97 | 2022-2025 | 3c Patch Kit - Box |
| Astrazeneca Pharmaceuticals LP | $189.27 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Kerecis Limited | $173.19 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Novo Nordisk INC | $98.37 | 2019-2025 | Wegovy |
| Organogenesis INC. | $93.64 | 2024-2025 | Puraply Wound Matrix |
| Lilly USA, LLC | $91.87 | 2021-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $79.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $72.85 | 2022-2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Next Science LLC | $61.53 | 2021-2024 | Surgx, Blastx, Xperience |
| Glaxosmithkline, LLC. | $58.82 | 2023-2025 | Trelegy Ellipta |
| Biowound Solutions, INC. | $58.72 | 2025 | Bio-Connekt |
| Janssen Pharmaceuticals, INC | $57.46 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.74 | 2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.77 | 2022-2023 | |
| Pfizer INC. | $41.11 | 2020-2021 | |
| Convatec INC. | $39.00 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.84 | 2023-2024 | Xifaxan |
| Dexcom, INC. | $24.15 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amarin Pharma, INC. | $24.09 | 2021 | |
| Hydrofera LLC | $23.84 | 2023 | Hydrofera Blue |
| Integra Lifesciences Corporation | $22.82 | 2020 | |
| Tei Medical INC. | $21.03 | 2019 | |
| Edwards Lifesciences Corporation | $19.42 | 2023 | Sapien 3 Ultra Resilia |
| Eisai INC. | $18.28 | 2021 | |
| Insulet Corporation | $18.24 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $16.17 | 2021 | |
| Solventum Corporation | $14.31 | 2024 | Activ.A.C. |
| Idorsia Pharmaceuticals US INC | $13.92 | 2023 | Quviviq |
| Exact Sciences Corporation | $13.80 | 2025 | Cologuard Collection Kit |
| Kci USA, INC. | $12.58 | 2021 | |
| Osiris Therapeutics INC. | $11.47 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $8.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.